Biology and therapy of prostatic cancer.

H. Schulze, John Tod Isaacs

Research output: Contribution to journalArticle

Abstract

There is no effective therapy for increasing the survival of metastatic prostatic cancer. New approaches to this major disease are urgently needed. One approach is to study the biology of prostatic carcinogenesis in order to develop a treatment that prevents the initial development of clinically manifest prostatic cancer. International epidemiological data on the incidence of prostatic cancer and the data on migrant populations make this both possible and practical. For example, it should be possible to lower the incidence of clinical prostatic cancer by more than ten-fold among men in the United States. An alternative approach is to study the tumour biology of prostatic cancer to identify better methods for treating established clinical prostatic cancer. Such studies have already demonstrated that individual prostatic cancers are composed of clones of cancer cells that are phenotypically heterogeneous even before therapy is initiated. Because of this tumour cell heterogeneity, future studies should be directed towards combining androgen ablation plus chemotherapy and/or radiation early in the disease in order to affect both the androgen-dependent and the androgen-independent cancer cells present in individual prostatic cancers.

Original languageEnglish (US)
Pages (from-to)487-503
Number of pages17
JournalCancer Surveys
Volume5
Issue number3
StatePublished - 1986
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Androgens
Therapeutics
Neoplasms
Incidence
Carcinogenesis
Clone Cells
Radiation
Drug Therapy
Survival
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Biology and therapy of prostatic cancer. / Schulze, H.; Isaacs, John Tod.

In: Cancer Surveys, Vol. 5, No. 3, 1986, p. 487-503.

Research output: Contribution to journalArticle

Schulze, H & Isaacs, JT 1986, 'Biology and therapy of prostatic cancer.', Cancer Surveys, vol. 5, no. 3, pp. 487-503.
Schulze, H. ; Isaacs, John Tod. / Biology and therapy of prostatic cancer. In: Cancer Surveys. 1986 ; Vol. 5, No. 3. pp. 487-503.
@article{2a158fed1681476d9d60ba4f5e2a98c8,
title = "Biology and therapy of prostatic cancer.",
abstract = "There is no effective therapy for increasing the survival of metastatic prostatic cancer. New approaches to this major disease are urgently needed. One approach is to study the biology of prostatic carcinogenesis in order to develop a treatment that prevents the initial development of clinically manifest prostatic cancer. International epidemiological data on the incidence of prostatic cancer and the data on migrant populations make this both possible and practical. For example, it should be possible to lower the incidence of clinical prostatic cancer by more than ten-fold among men in the United States. An alternative approach is to study the tumour biology of prostatic cancer to identify better methods for treating established clinical prostatic cancer. Such studies have already demonstrated that individual prostatic cancers are composed of clones of cancer cells that are phenotypically heterogeneous even before therapy is initiated. Because of this tumour cell heterogeneity, future studies should be directed towards combining androgen ablation plus chemotherapy and/or radiation early in the disease in order to affect both the androgen-dependent and the androgen-independent cancer cells present in individual prostatic cancers.",
author = "H. Schulze and Isaacs, {John Tod}",
year = "1986",
language = "English (US)",
volume = "5",
pages = "487--503",
journal = "Cancer Surveys",
issn = "0261-2429",
publisher = "Cold Spring Harbor Laboratory Press",
number = "3",

}

TY - JOUR

T1 - Biology and therapy of prostatic cancer.

AU - Schulze, H.

AU - Isaacs, John Tod

PY - 1986

Y1 - 1986

N2 - There is no effective therapy for increasing the survival of metastatic prostatic cancer. New approaches to this major disease are urgently needed. One approach is to study the biology of prostatic carcinogenesis in order to develop a treatment that prevents the initial development of clinically manifest prostatic cancer. International epidemiological data on the incidence of prostatic cancer and the data on migrant populations make this both possible and practical. For example, it should be possible to lower the incidence of clinical prostatic cancer by more than ten-fold among men in the United States. An alternative approach is to study the tumour biology of prostatic cancer to identify better methods for treating established clinical prostatic cancer. Such studies have already demonstrated that individual prostatic cancers are composed of clones of cancer cells that are phenotypically heterogeneous even before therapy is initiated. Because of this tumour cell heterogeneity, future studies should be directed towards combining androgen ablation plus chemotherapy and/or radiation early in the disease in order to affect both the androgen-dependent and the androgen-independent cancer cells present in individual prostatic cancers.

AB - There is no effective therapy for increasing the survival of metastatic prostatic cancer. New approaches to this major disease are urgently needed. One approach is to study the biology of prostatic carcinogenesis in order to develop a treatment that prevents the initial development of clinically manifest prostatic cancer. International epidemiological data on the incidence of prostatic cancer and the data on migrant populations make this both possible and practical. For example, it should be possible to lower the incidence of clinical prostatic cancer by more than ten-fold among men in the United States. An alternative approach is to study the tumour biology of prostatic cancer to identify better methods for treating established clinical prostatic cancer. Such studies have already demonstrated that individual prostatic cancers are composed of clones of cancer cells that are phenotypically heterogeneous even before therapy is initiated. Because of this tumour cell heterogeneity, future studies should be directed towards combining androgen ablation plus chemotherapy and/or radiation early in the disease in order to affect both the androgen-dependent and the androgen-independent cancer cells present in individual prostatic cancers.

UR - http://www.scopus.com/inward/record.url?scp=0022851604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022851604&partnerID=8YFLogxK

M3 - Article

C2 - 3555779

AN - SCOPUS:0022851604

VL - 5

SP - 487

EP - 503

JO - Cancer Surveys

JF - Cancer Surveys

SN - 0261-2429

IS - 3

ER -